Vivlion offers PRCISR™ CRISPR screening solutions to advance research in functional genomics and drug discovery. Vivlion's 3Cs technology enables the production of uniformly distributed gRNA libraries in single or combinatorial format. Solutions range from pooled and arrayed gRNA.

For more than 35 years, Integrated DNA Technologies, Inc. (IDT) has been empowering genomics laboratories with an oligonucleotide manufacturing process unlike anyone else in the industry, with the most advanced synthesis, modification, purification, and quality control capabilities available. Since its founding in 1987, IDT has progressed from a leading oligo manufacturer to a genomics solutions provider supporting key application areas such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP* services, IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases. As the company seeks to fulfill its mission of accelerating the pace of genomics, the important acquisition of Archer™ NGS Research Assays was completed in Dec. 2022. When combined with its existing solutions, the expanded portfolio helps realize the shared vision of enabling researchers to rapidly move from the lab to life-changing advances.

Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, RNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies, and other treatments. Headquartered in Fargo, North Dakota, and as a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people.

ChemoMetec is a leading manufacturer of high-precision cell counting and analysis equipment.

Our robust Xcytomatic® and NucleoCounter® instruments are the most precise automated cell counters on the market and enable the development of reproducible processes and cGMP manufacturing of biological products.

The stellar support we offer from our field application scientists and engineers help thousands of biopharma customers integrate commercial-ready cell counting processes across sites. No matter the sample, location or user, our technology ensures consistent performance.

Agilent has been manufacturing oligonucleotide therapeutics since 2006. Our cGMP facilities support clinical-grade production of CRISPR sgRNA, siRNA, and antisense, from grams to kilograms. In 2027, Agilent will launch a dedicated CRISPR sgRNA manufacturing train. The BioVectra CDMO acquisition added sterile fill-finish and biologics capabilities for comprehensive gene editing.

Ampliqon is a global leader in production of PCR Enzymes and custom made laboratory reagents.

Unleash the full potential of your nucleic acid technology!

BioSpring is a leading industry expert in oligonucleotide science and technology, specializing in high-quality cGMP manufacturing and analytics for commercial programs and clinical phases I-III, in addition to preclinical material supply and diagnostic manufacturing. We are a privately owned company of 555 employees committed to providing expert support through all phases and regulatory filings, including highly flexible and customizable solutions to accelerate therapeutic programs through the entire drug development lifecycle. Our global clients rely on our quality and expertise, guided by our passion for innovation and over 26 years of experience.

Broken String Bioscience’s technology platform, INDUCE-seq® supports the development of cell and gene therapies that are safer by design. INDUCE-seq™, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs.

Caszyme is a biotech company based in Vilnius, Lithuania, specializing in CRISPR-Cas gene editing technology development, application, and novel Molecular Tools. We empower partners looking to leverage CRISPR with our deep expertise, backed by a highly flexible platform of characterized nucleases, enabling the development of market-ready products across multiple industries.

Countagen develops cutting-edge gene editing analysis tools to enable and accelerate access to the transformative power of gene editing. Our mission is to pioneer excellence in the development and discovery of gene and cell therapies.

GeneAbacus, our flagship product, utilizes the unique technology of padlock probes and rolling circle amplification to speed up and simplify the gene targeting validation process. This assay removes the need for PCR and can be done completely in-house with standard laboratory instrumentation. We are able to bring extracted DNA to quantified data in under 5 hours, with minimal hands-on time and digital quantification precision.

Click to learn more.

GenScript Biotech offers comprehensive gene synthesis, DNA and RNA oligo synthesis with specialties in CRISPR sgRNA/NGS/qPRC/tRNA/siRNA oligos, IVT mRNA/circRNA synthesis and LNP formulation, as well as peptide synthesis, protein and antibody production services. GenScript Biotech can also offer peptides as well as CRISPR services from research use to cGMP needs.

HuidaGene Therapeutics utilizes its proprietary CRISPR-based HG-PRECISE platform to develop potentially curative genome medicines.

Lonza Bioscience Solutions provides life science researchers in academic and government institutions as well as major biotech and pharmaceutical organizations worldwide with the tools they need to develop and test critical disease-treating drugs and therapies, from basic research to final product release, including cell culture and discovery technologies, quality control tests and software for biomanufacturing.

Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with the tools they need to better measure, characterize, and predict our resistance and response to new therapies. Mission Bio’s multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health. The company’s Tapestri Platform is being utilized by customers at leading research centers, pharmaceutical, and diagnostics companies worldwide. A Tapestri assay recently entered GMP qualification and validation, indicating that single-cell analysis is on its way to routine use in clinical trials to support the next wave of life-saving CGT treatments.

At Moligo we have developed a novel enzymatic synthesis technology that generates DNA strands with unprecedented purity, length and complexity, and at industrial scale. We support partners developing new gene-based therapies and technologies with the mission of making them better, safer and accessible for everyone.